Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 4/20 | 0.54 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.54 |
| ▸ | PARP1 | P09874 | 4/20 | 0.53 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.53 |
| ▸ | PLAU | P00749 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.51 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10247994 | 0.85 | PARP1 (0.54) | KMT2AKCNK3KCNK9PARP1MEN1 | |
| SCHEMBL4004339 | 0.84 | KCNK3 (0.76) | KMT2AKCNK3KCNK9PARP1PARP15 | |
| SCHEMBL10090679 | 0.83 | PARP1 (0.74) | KMT2AKCNK3KCNK9PARP1PARP15 | |
| SCHEMBL15899948 | 0.82 | CYP1A2 (0.55) | ATRKMT2APARP1PARP15PARP10 | |
| SCHEMBL21446741 | 0.82 | KDR (0.61) | ATRKMT2APLAUMEN1 | |
| SCHEMBL10248292 | 0.81 | KMT2A (0.60) | ATRKMT2AMEN1 | |
| SCHEMBL15824064 | 0.80 | KIT (0.66) | ATRKMT2APARP1PARP15PARP10 | |
| SCHEMBL10248025 | 0.79 | MAPT (0.64) | KMT2AKCNK3MEN1 | |
| SCHEMBL3096639 | 0.78 | KCNQ3 (0.52) | ATRKMT2AKCNK3KCNK9PARP1 | |
| SCHEMBL28031075 | 0.78 | KCNK3 (0.77) | KMT2AKCNK3KCNK9PLAUSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | ATR 2558/4885KMT2A 3407/4885KCNK3 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.